Yarrow Bioscience
YARW
42 hedge funds and large institutions have $7.89M invested in Yarrow Bioscience in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 4
47% more capital invested
Capital invested by funds: $5.35M → $7.89M (+$2.54M)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
11.91% more ownership
Funds ownership: 27.73% → 39.64% (+12%)
0% more funds holding
Funds holding: 42 → 42 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$950K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$583K |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$534K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$473K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$150K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$31K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$24.8K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$18.3K |
| 5 |
VF
Virtu Financial
New York
|
-$15K |
YARW Hedge Fund Activity: Q1 2026 in Review
42 of the 8,197 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience (YARW) for Q1 2026, worth a combined $7.89M — up 47% from $5.35M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new YARW positions and 5 closed out — a net gain of 2 holders — while 10 added to existing stakes and 4 trimmed.
The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $950K. The largest seller was Acadian Asset Management, cutting an estimated $150K.
- 42 institutional investors held Yarrow Bioscience (YARW) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $7.89M of Yarrow Bioscience stock for Q1 2026, up 47% quarter-over-quarter.
- 7 funds opened new Yarrow Bioscience positions in Q1 2026 and 5 closed out, a net change of +2 holders.
- The largest Yarrow Bioscience buyer in Q1 2026 was Lynx1 Capital Management, an estimated $950K added.
- The largest Yarrow Bioscience seller in Q1 2026 was Acadian Asset Management, an estimated $150K sold.
Based on aggregated 13F filings for Q1 2026.